Intercept receives Innovation Award from the National Organization for Rare Disorders
Intercept Pharma announced that it has received a 2017 Industry Innovation Award from the National Organization for Rare Disorders for the development of Ocaliva (obeticholic acid). Ocaliva is indicated in the U.S. and EU for treatment of PBC in combination with UDCA in adults. May 19, 2017